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A replicon vaccine vector system was developed from an attenuated strain of Venezuelan equine encephalitis virus (VEE).
The replicon RNA consists of the cis-acting 59 and 39 ends of the VEE genome, the complete nonstructural protein gene
region, and the subgenomic 26S promoter. The genes encoding the VEE structural proteins were replaced with the influenza
virus hemagglutinin (HA) or the Lassa virus nucleocapsid (N) gene, and upon transfection into eukaryotic cells by electro-
poration, these replicon RNAs directed the efficient, high-level synthesis of the HA or N proteins. For packaging of replicon
RNAs into VEE replicon particles (VRP), the VEE capsid and glycoproteins were supplied in trans by expression from helper
RNA(s) coelectroporated with the replicon. A number of different helper constructs, expressing the VEE structural proteins
from a single or two separate helper RNAs, were derived from attenuated VEE strains. Regeneration of infectious virus was
not detected when replicons were packaged using a bipartite helper system encoding the VEE capsid protein and
glycoproteins on two separate RNAs. Subcutaneous immunization of BALB/c mice with VRP expressing the influenza HA or
Lassa virus N gene (HA-VRP or N-VRP, respectively) induced antibody responses to the expressed protein. After two
inoculations of HA-VRP, complete protection against intranasal challenge with influenza was observed. Furthermore,
sequential immunization of mice with two inoculations of N-VRP prior to two inoculations of HA-VRP induced an immune
response to both HA and N equivalent to immunization with either VRP construct alone. Protection against influenza
challenge was unaffected by previous N-VRP immunization. Therefore, the VEE replicon system was characterized by
high-level expression of heterologous genes in cultured cells, little or no regeneration of plaque-forming virus particles, the
capability for sequential immunization to multiple pathogens in the same host, and induction of protective immunity against
a mucosal pathogen. © 1997 Academic Press
INTRODUCTION
The alphaviruses, a genus in the family Togaviridae,
possess a single-stranded, positive-sense RNA genome
enclosed in a relatively simple virion structure (reviewed
in Strauss and Strauss, 1994). The icosahedral nucleo-
capsid consists of 240 copies of a single capsid protein
and is surrounded by a lipoprotein envelope containing
two viral glycoproteins, E1 and E2. The capsid, E1, and
E2 genes are expressed from a subgenomic 26S mRNA
produced in infected cells. The 26S mRNA promoter
drives transcription of the subgenomic RNA such that it
is present at up to 10 times the amount of genomic (or
42S) RNA on a molar basis. Capsid monomers and the
genomic RNA assemble into nucleocapsids in the cyto-
plasm. Glycoproteins E1 and PE2, the precursor to E2,
are inserted into the endoplasmic reticulum and pro-
cessed through the Golgi where a cellular protease,
furin, cleaves PE2 into E2 and E3, the amino-terminal
portion of PE2.
Vector systems for the expression of heterologous
genes have been developed from full-length cDNA
clones of three members of the alphavirus genus, Sind-
bis virus, Semliki Forest virus (SFV), and Venezuelan
equine encephalitis virus (VEE) (Xiong et al., 1989; Huang
et al., 1989; Liljestro¨m and Garoff, 1991; Bredenbeek et
al., 1993; Zhou et al., 1994; Davis et al., 1996; Dryga et al.,
1996; reviewed in Frolov et al., 1996). The systems are of
two general types: ‘‘double promoter’’ vectors and ‘‘repli-
con’’ vectors. In the double promoter vectors, a second
copy of the 26S promoter is inserted into the genome
either immediately upstream of the authentic promoter or
between the E1 gene and the beginning of the 39 un-
translated region. A heterologous gene is then inserted
into the genome just downstream of the second 26S
promoter such that a second subgenomic mRNA con-
taining the heterologous gene is transcribed. These vec-
tors replicate in infected cells and assemble into infec-
tious particles which can spread to other cells and again
express the heterologous gene. When such vectors are
based on vaccine strains of alphaviruses, they can be
utilized in vivo for immunization against both the alpha-
virus vector and the pathogen from which the heterolo-
gous gene was derived (Hahn et al., 1992; Davis et al.,
1996; Caley et al., 1997).
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In alphavirus replicon vectors, the viral structural pro-
tein genes are deleted and replaced by a heterologous
gene under the control of the 26S promoter. The struc-
tural genes are provided in trans from a helper con-
struct(s) consisting of a partial clone of the viral genome
which is missing all or part of the genes for the nonstruc-
tural proteins, including the putative cis-acting RNA
packaging signals (Weiss et al., 1989, 1994). Both the
replicon and the helper RNAs retain the cis-acting termi-
nal sequences required for genome replication and the
promoter for transcription of the subgenomic mRNA. The
replicon RNA supplies the nonstructural proteins in trans
for the expression of the helper RNA. However, only the
replicon RNA retains the packaging signal(s), and it is
packaged into replicon particles by the viral structural
proteins provided in trans by the helper. Infection of cells
by these replicon particles results in amplification of
replicon RNA and expression of the heterologous gene,
but there is no further spread to other cells.
Alphavirus replicon vectors have been utilized for vac-
cination against microbial pathogens (Zhou et al., 1995;
Mossman et al., 1996) and offer several potential advan-
tages as vaccine delivery systems. Replicons typically
express heterologous genes to high levels, suggesting
that a relatively low dose of replicon particles would
produce a large dose of immunogen in vivo. They do not
contain a complete complement of viral genes, so that
after replication and expression of the heterologous
gene in the cells initially infected, no additional infectious
particles would be produced to spread to other tissues.
This property contributes significantly to the inherent
safety of alphavirus replicon vectors. In addition, the
self-limiting nature of the replicon particle infection and
the lack of structural protein expression should minimize
the induction of an immune response to the vector, al-
lowing the sequential use of these vectors for immuni-
zation of the same individual with immunogens of differ-
ent pathogens. In practice however, infectious virus is
frequently regenerated through copackaging of helper
and replicon RNAs (Geigenmu¨ller-Gnirke et al., 1991) or
recombination between these molecules (Weiss and
Schlesinger, 1991; Raju et al., 1995). The presence of
copackaged and/or recombinant virus in replicon prep-
arations may increase the chance of inducing immunity
to the vector itself and limit its usefulness for subsequent
vaccination against other pathogens. In addition, there
remain substantial concerns regarding the conse-
quences of disease due to infection by recombinant
replication-competent virus in a vaccine preparation (Wil-
lems et al., 1979).
VEE is the only alphavirus for which a live, attenuated
vaccine strain (TC-83) has been developed for veterinary
and human use (Jahrling and Stephenson, 1984; Kinney
et al., 1993). New live, attenuated VEE vaccines, which
offer significant improvements over TC-83, have been
developed from a full-length cDNA clone (Davis et al.,
1989), by the introduction of multiple attenuating muta-
tions into the structural protein genes. Thus, vectors
derived from such vaccine strains are inherently safer
than those derived from wild-type virus. Several of these
strains, including V3014, replicate in lymphoid tissue
without causing disease (Grieder et al., 1995; Davis et al.,
1996). In the context of a vector, the VEE glycoproteins
will preferentially target heterologous gene expression to
lymphoid tissues (Davis et al., 1996; Caley et al., 1997),
which may result in increased immunogenicity of the
heterologous gene product.
In this study, two strategies were examined for improv-
ing the safety and efficacy of a VEE-based replicon
vector. One strategy was to include previously defined
attenuating mutations in the replicon and/or its helper. In
this way, any viable recombinant virus is prevented from
initiating a virulent infection. A second approach used a
bipartite helper to supply structural proteins for packag-
ing of the replicon into particles, thus requiring at least
two recombination events for the generation of viable
virus. This strategy greatly reduced the probability that a
viable recombinant VEE virus would be generated during
packaging. Using a VEE replicon particle (VRP) vaccine
prepared in this manner, we have demonstrated the
induction of high-level, protective immunity to a heterol-
ogous mucosal pathogen in naive animals and have
achieved an equally high level, protective response in
animals previously immunized with VRP-expressing
genes from another pathogen.
MATERIALS AND METHODS
Cell lines and plasmids
Primary chicken (CEF) and duck (DEF) embryo fibro-
blasts, baby hamster kidney (BHK), and Vero cell lines
were maintained in minimal essential medium with Ear-
le’s salts, 10% fetal bovine serum, 200 U/ml penicillin, 200
mg/ml streptomycin, and 10 mg/ml gentamicin sulfate.
Full-length VEE clones pV3014, pV3519, and pV3526 were
previously derived by mutagenesis of pV3000, a cDNA
clone of the Trinidad donkey strain of VEE (Davis et al.,
1989, 1991, 1995; Grieder et al., 1995). The VEE cDNA is
downstream from a T7 RNA polymerase promoter such
that linearization of the clone downstream of the VEE
sequences, and subsequent in vitro transcription with T7
polymerase, yields infectious VEE genomic replicas
(Davis et al., 1989, 1991, 1995) (Fig. 1A). Plasmid
pLS5560-7A, containing the N gene of the Josiah strain of
the Lassa virus, was obtained from D. Auperin (CDC,
Atlanta). The cloned HA gene of influenza A/PR/8/34
(H1N1) was obtained from P. Palese (Mount Sinai School
of Medicine, New York).
The VEE replicon was prepared from a plasmid carry-
ing a complete cDNA copy of the VEE genome modified
to contain a second 26S promoter followed by a multiple
cloning site from Cla12 adaptor plasmid (Hughes et al.,
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1987). The double promoter clone was digested with
ApaI, which cleaves within the 26S promoters bracketing
the structural protein genes. Religation reconstituted a
single 26S promoter followed by a multiple cloning site,
which was used for insertion of the influenza HA or the
Lassa N genes (Fig. 1B). To facilitate the cloning of these
and other genes, a shuttle vector also was constructed
(Davis et al., 1996).
The helper constructs were derived from the
pV3014, pV3519, and pV3526 clones by partial deletion
of the genes encoding the VEE nonstructural proteins
(Fig. 1C). When necessary, incompatible 59 and 39
overhanging ends were made blunt by treatment with
T4 DNA polymerase prior to religation of the plasmid.
As cDNA clones of three attenuated strains of VEE
were used, the helpers differed not only in the length
of the deletion, but also in the mutations within the
genes encoding the virus glycoproteins (Table 1). Be-
cause certain relatively short in-frame deletions in the
nonstructural genes are compatible with viability
(Davis et al., 1989), frame-shift mutations were in-
serted in V3014D2307–3055 and V3014D1951–3359 at
the site of the deletions in order to terminate transla-
tion of the residual downstream reading frame.
The bipartite helper system consisted of individual
Capsid (C)- and glycoprotein (GP)-helper RNAs which
were constructed from V3014D520–7505. In the C-
helper, nt 8495–11229 were deleted by digestion of
V3014D520–7505 with HpaI and religation of the 3.8-kb
DNA fragment. In the GP-helper, nt 7565–8386 were
deleted by digestion of V3014D520–7505 with Tth111I
and SpeI followed by ligation of the 5.7-kb DNA frag-
ment with the synthetic double-stranded oligonucleo-
tide 59-TAGTCTAGTCCGCCAAGATGTCA-39. This oligo-
nucleotide contained Tth111I and SpeI overhanging
ends at the 59 and 39 ends, respectively, and reconsti-
tuted the 26S promoter downstream from the Tth111I
site, the initiation codon normally used for the capsid
protein, and the first codon of E3.
Transcription and transfection
Plasmid templates were linearized by digestion with
NotI at a unique site downstream from the VEE cDNA
sequence, and capped run-off transcripts were prepared
in vitro with the RiboMAX T7 RNA polymerase kit (Pro-
mega). BHK cells were transfected by electroporation
(Liljestro¨m and Garoff, 1991) and incubated in 75-cm2
flasks at 37°C in 5% CO2. For the preparation of VRP,
transcripts of both the replicon and the helper plasmids
were coelectroporated into BHK cells, and the culture
supernatants were harvested at 30 hrs after transfection.
Analysis of expression products and titration of VRP
Subconfluent cell monolayers were infected with VRP
(m.o.i. 5 5) or transfected with RNA by electroporation.
Cells were harvested at the times indicated in the text,
and expressed polypeptides were separated by poly-
acrylamide gel electrophoresis (Laemmli, 1970) and ex-
amined by Western blotting (Towbin et al., 1979). To
determine transfection efficiencies or the titers of various
VRP preparations, BHK cells were transfected with RNA
or infected with serial dilutions of VRP and incubated in
eight-chamber slides (Nunc) for 20 h at 37°C to allow
expression of HA, N, or VEE proteins. Antigen-positive
cells were then enumerated for Lassa N protein by direct
immunofluorescence using a FITC-conjugated monkey
anti-Lassa serum or for influenza HA protein by indirect
immunofluorescence as previously described (Pifat et
al., 1988) using the HA-specific monoclonal antibody
37-85 (Staudt and Gerhard, 1983) obtained from S.
Clarke, University of North Carolina.
Immunization of mice with VRP
VRP were prepared by clarification of culture superna-
tants from cotransfected cells at 4000g for 10 min. Alter-
natively, VRP were purified further and concentrated by
centrifugation at 39,000 rpm in an SW41 rotor through a
cushion of 20% sucrose in PBS. The VRP preparations
were diluted in Hank’s balanced salt solution (HBSS),
and groups of 6- to 8-week old BALB/c mice were inoc-
ulated with either a single dose of 0.2 ml subcutaneously
(sc; HA-VRP) or 0.1 ml sc and 0.1 ml intraperitoneally
(N-VRP). For booster immunizations, animals received
identical inoculations at the times indicated. Control
mice were inoculated with HBSS. The animals were
observed daily and bled at 7- to 14-day intervals.
Enzyme-linked immunosorbent assay (ELISA)
Quantitation of VRP-induced serum antibodies was
performed by ELISA essentially as described previously
(Ludwig et al., 1996), except that purified and inactivated
Lassa virus or live VEE or influenza virus (A/PR8/34
(H1N1) was diluted in buffer containing 0.01 M Na2CO3
and 0.035 M NaHCO3, pH 9.6, and 400 ng/well was
adsorbed to plates for 12–15 h. Residual binding sites
were blocked with PBS containing 5% fish gelatin and
0.1% Tween 20. Negative control wells received serum
from mock immunized mice. Serum titers were ex-
pressed as the highest serum dilution resulting in optical
densities greater than the mean of the optical densities
of the negative controls plus three standard deviations.
Challenge with influenza virus
Animals were anesthetized with Metofane (Pitman-
Moore) and challenged by administration of 1 3 105 to
2 3 105 50% egg infectious doses (EID50) of influenza
A/PR/8/34 intranasally (i.n.) in 20 ml (10 ml in each naris).
Mice were observed and weighed daily for 14 days after
challenge.
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RESULTS
The objectives of these experiments were (1) to con-
struct VEE replicon RNAs capable of programming their
own replication and expressing a heterologous gene to
high level; (2) to develop packaging systems for the
production of VRP, which would greatly reduce the rate of
recombination between helper and replicon RNAs; (3) to
demonstrate the utility of VRP for induction of protective
immune responses to a heterologous pathogen; and (4)
to determine whether VRP may be used sequentially in
the same individual for immunization against multiple
pathogens.
Replicon and single helper constructs
Figure 1 shows the structures of the replicon and
helper constructs. The replicon RNAs retained all of the
cis-acting signals present in the VEE RNA genome, while
the genes for the structural proteins were deleted. The
influenza HA gene or the N gene from Lassa virus was
inserted into the replicon downstream of the 26S pro-
moter.
The helper constructs were derived from full-length
VEE cDNA clones which harbored different constella-
tions of attenuating mutations. This precaution was
taken so that in the event that recombination between
helper and replicon RNAs resulted in plaque-forming
virus, an attenuated VEE vaccine strain rather than viru-
lent virus would be generated. Three full-length cDNA
clones were assessed as possible sources of the helper
RNAs (Fig. 1). V3014 and V3519 contain substitution mu-
tations within the E2 and E1 glycoproteins (Davis et al.,
1991; Grieder et al., 1995). V3526, in addition to an atten-
uating amino acid change within E1, has a deletion of the
consensus furin cleavage site between the E3 and E2
glycoproteins so that V3526 virions incorporate the un-
processed pE2 glycoprotein precursor in place of the E2
glycoprotein (Davis et al., 1995). The helper constructs
were prepared by various partial deletions of the non-
structural protein genes of the pV3014, pV3519, and
pV3526 clones (Fig. 1C).
Expression of heterologous proteins from replicon
RNA
The expression in BHK cells of influenza virus HA and
Lassa virus N proteins from HA-replicon RNA and N-
replicon RNA, respectively, and of the VEE structural
proteins from the V3014D520–7505 RNA helper is shown
in Fig. 2. In this study, BHK cells were transfected by
electroporation, incubated for 30 h at 37°C, and analyzed
by Western blotting. In BHK cells transfected with N-
replicon RNA alone (data not shown) or cotransfected
with N-replicon RNA and the V3014D520–7505 helper
(Fig. 2, lane 3), a predominant polypeptide species of the
expected molecular mass (63 kDa) was detected with
monkey anti-Lassa antisera. In parallel studies with HA-
replicon RNA, the HA migrated as two species with
apparent molecular masses of 75–80 kDa. These prob-
ably represented glycosylation variants, as both bands
reacted with the HA-specific monoclonal antibody, 37–85
(Fig. 2, lane 1). The antibodies were unreactive with
control cells which were electroporated without RNA
(Fig. 2, lanes 2 and 4). The anti-VEE antiserum was
reactive with a protein in the control cell extract (Fig. 2,
lane 9), but as would be expected, neither a recombinant
replicon (Fig. 2, lane 7) nor a helper RNA alone (Fig. 2,
lane 8) directed the synthesis of VEE structural proteins
when transfected separately into BHK cells. However,
VEE structural proteins were produced in large amounts
in cells cotransfected with helper and replicon RNAs
(Fig. 2, lane 6), and these proteins comigrated with au-
thentic V3014 proteins (Fig. 2, lane 5).
Packaging of VEE replicon RNAs in cotransfected
cells
Packaging signals for alphavirus RNAs have been
described in both nonstructural (Weiss et al., 1989,
1994) and structural genes (Rumenapf et al., 1995), but
remain undefined for VEE. However, efficient packag-
ing of N-replicon and HA-replicon RNAs with several
of the helper RNAs (Table 1) demonstrates that pack-
aging signals are present in the VEE replicon RNAs,
presumably in the nonstructural genes, as shown for
Sindbis virus (Weiss et al., 1989) and SFV (Liljestro¨m
and Garoff, 1991). To determine whether the size or
position of the nonstructural gene deletions in the
helper RNAs influenced the efficiency of packaging,
the N-replicon RNA was packaged by coelectropora-
tion with a series of helpers prepared by deleting
varying portions of the nonstructural protein genes
(Table 1). Titration of released VRP was readily accom-
plished by enumeration of antigen-positive cells by
immunofluorescence. Titers approaching 108 IU/ml
were obtained when either the Lassa N or the influ-
enza HA replicon was coelectroporated with a V3014-
derived helper from which nt 520–7505 (90%) of the
nonstructural genes were deleted. The titers were
reduced when helpers had shorter deletions or were
derived from V3519 or V3526 strains of VEE. The rea-
sons for the lower packaging efficiency with these
helpers are unknown. However, previous studies
which examined complementation among alphavirus
temperature-sensitive mutants also found that
complementation was highly dependent on the spe-
cific virus and specific strains used (Burge and Pfef-
ferkorn, 1966; Tan et al., 1969; Kera¨nen and Ka¨a¨ria¨nen,
1974; Atkins et al., 1974; Strauss et al., 1976; Hashimoto
and Simizu, 1978; Maeda et al., 1979; reviewed in
Strauss and Strauss, 1980).
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FIG. 1. Structure of VEE replicon and helper RNAs. (A) VEE full-length cDNA clones and infectious RNA. Restriction sites and numbering are according
to Kinney et al., (1993). Open arrow shows the position of the T7 RNA polymerase promoter and direction of in vitro transcription. Also indicated are the
59-cap, 26S promoter (shaded arrow), genes encoding nonstructural (solid line) and structural proteins (capsid, hashed bar; glycoproteins, solid bar), and
the 39-poly(A). (B) VEE replicons. The HA-replicon and N-replicon RNAs were similar to the full-length RNA except that the open reading frame encoding the
VEE structural proteins in the full-length RNA was replaced with the HA or N genes, respectively. Nucleotides of VEE, as well as of the HA and N genes
(italics) are shown. (C) Helper constructs. The helper RNAs are isogenic to the VEE full-length RNA, with the exception of the deletions (dashed lines) in the
nonstructural region. The parental attenuated VEE strains and the deletions are listed on the left. The deletions were generated using the restriction sites
shown in A. (D) Bipartite helper RNAs. The bipartite helper system consisted of two helper RNAs derived from the V3014D520–7505 monopartite helper. One
RNA expressed the VEE capsid gene, and the second RNA expressed the glycoprotein genes.
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Expression of heterologous proteins in different cell
lines infected with VRP
Lassa N-replicon RNAs were packaged using the
V3014D520–7505 helper, and the resulting N-VRP were
used to infect BHK, Vero, CEF, and DEF cells at a m.o.i. of
5 (Fig. 3). By 48 h postinfection, large amounts of N were
evident. Densitometric analysis of several such gels from
BHK cell extracts indicated that approximately 20% of the
total cellular protein was Lassa N. This study shows that
VRP have a broad host range as specified by the VEE
glycoproteins and can induce high-level protein expres-
sion in a variety of cell types.
Recombination between replicon and monopartite
helper RNAs
Existing alphavirus replicon systems produce signifi-
cant levels of live, plaque-forming virus in addition to
packaged replicons due to recombination between the
replicon and the helper RNAs (Weiss and Schlesinger,
1991; Bredenbeek et al., 1993). Significant amounts of
infectious virus also were evident in cells transfected
with the VEE replicon and the various monopartite helper
RNAs. As shown in Table 1, infectious virus titers of ,102
to 2 3 105 PFU/ml (limit of detection 5 102) were pro-
duced, and the amount of plaque-forming virus appeared
to be dependent on the specific helper used (Table 1).
Although the packaging of replicons was much less
efficient with V3519-derived helpers, no infectious virus
was detected by direct plaque assay of the replicon
preparations (Table 1). However, when BHK cells were
inoculated with media from cells coelectroporated with
the replicon and the V3519D520–7505 helper, cytopathol-
ogy was evident by 48 h, and virus was then readily
detectable by plaque assay (data not shown).
TABLE 1
Replicon Packaging in BHK Cells Cotransfected with Lassa N-Replicon and Helper RNAsa





V3519 E2 E76K; E2 E209K V3519 D1955–3359 ,10 ,100
E1 A272T V3519 D1687–7505 ndf ,100
V3519 D3958–7505 ,10 ,100
V3519 D520–7505 6 3 105 ,100
V3526 E3 D56RKRR59 V3526 D520–7505 3 3 104 3 3 102
E1 F253S
V3014 E2 E209K; E2 I239N V3014 D2307–3055 nd 1 3 104
E1 A272T V3014 D2311–3055 nd 1 3 104
V3014 D1951–3359 nd 2 3 105
V3014 D1955–3359 6 3 106 1 3 105
V3014 D3958–7505 1 3 104 2 3 105
V3014 D2311–7505 4 3 104 3 3 104
V3014 D520–3954 2 3 107 4 3 103
V3014 D520–6965 5 3 105 2 3 103
V3014 D520–7505 8 3 107 2 3 103
V3014-Bipartite helper 1 3 108 ,100
a Cotransfection of BHK cells with the Lassa virus N-replicon and the helper indicated; cotransfections with the HA-replicon yielded similar titers.
b Amino acid substitutions compared to the V3000 sequence.
c Designated by the parental VEE strain used for construction and the region of the VEE NS region deleted.
d As determined by infection of BHK cells with VRP and enumeration of infected cells by immunofluorescence.
e As determined by direct plaque assay in Vero cells.
f nd, not determined.
FIG. 2. Synthesis of influenza HA, Lassa N, and VEE structural
proteins in transfected BHK cells. BHK cells were coelectroporated
with RNAs of the HA-replicon and V3014D520–7505 helper (lane 1) or
N-replicon and V3014D520–7505 (lanes 3 and 6) or electroporated with
individual RNAs of V3014 (lane 5), N-replicon (lane 7), or V3014D520–
7505 (lane 8). Lanes 2, 4, and 9 represent BHK cells electroporated
without RNA. Cell extracts were collected at 30 h postelectroporation
as described under Materials and Methods. Each lane was loaded with
the equivalent of 5 3 104 cells. Proteins were visualized by immuno-
blotting with an anti-HA monoclonal antibody (37–85; lanes 1 and 2) or
monkey anti-Lassa serum (lanes 3 and 4). VEE structural proteins were
visualized by immunoblotting with rabbit anti-VEE serum. Positions of
VEE PE2, E1, E2, and capsid proteins are shown. The minor band
present in all lanes likely represents a cellular protein cross-reacting
with the anti-VEE serum.
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Although decreasing the size of the available homol-
ogous sequences between replicon and helper RNA
appeared to reduce the levels of plaque-forming virus,
infectious virus was found with each of the helper RNAs
tested, even when 90% of the nonstructural gene region
was deleted as in the V3014D520–7505 helper. Partial
sequence analysis of three plaque isolates from different
packaging experiments with the V3014D520–7505 helper
demonstrated that in each case, the virus was a recom-
binant rather than the result of copackaging of helper
and replicon RNAs (Table 2). For each isolate, nonho-
mologous recombination had occurred at a different
point within the heterologous gene insert, resulting in the
substitution of the 39 portion of the HA gene insert and
the 39 untranslated region of the replicon RNA with a
second 26S promoter, the VEE structural protein genes
and the 39 untranslated region of the helper RNA.
Generation of VRP using bipartite helper RNAs
To decrease the probability of recombination, a bipar-
tite packaging system was engineered to increase the
number of recombination events required to regenerate
an infectious virus. The bipartite helper encoded the VEE
capsid and the V3014 mutant glycoproteins on two sep-
arate helper RNAs (Fig. 1D), analogous to a helper sys-
tem independently developed for packaging of Sindbis
replicons (Frolov et al., 1997). Coelectroporation of the
three RNAs (either HA or N replicon RNA and the two
RNAs composing the bipartite helper) resulted in repli-
con packaging at levels equivalent to the best yields
obtained when a monopartite helper was used (Table 1).
In addition, infectious virus was not detected in these
experiments by plaque assay (limit of detection was 20
PFU/ml). Blind passage of supernatants from transfected
cells and infectious center assays also detected no via-
ble virus (limit of detection was 1 PFU/ml and 5 PFU/ml,
respectively). Intracerebral (ic) inoculation of suckling
mice (Table 3) also failed to provide any evidence of the
regeneration of virulent infectious virus (limit of detection
was 64 mouse lethal doses/ml). These results demon-
strated that the preparation of high-titer VRP, free of
detectable plaque-forming virus and offering a signifi-
cantly enhanced level of safety, was feasible with a
bipartite helper system.
FIG. 3. Expression of Lassa N in cultured cells infected with N-VRP.
N-VRP were prepared in BHK cells using the V3014D520–7505 helper.
Subconfluent monolayers were infected at an m.o.i. of 5, and cells were
harvested 48 h postinfection and processed for electrophoresis and
staining with Coomassie Blue dye as described under Materials and
Methods. Lysates of infected and uninfected cells are indicated with (a)
and (b), respectively. Position of the Lassa N protein is indicated.
TABLE 2
Recombination Points in Plaque-Forming Viruses
59 nucleotide
from HA replicona
39 nucleotide from helper
V3014D520–7505b
nt 1 788 nt 391
nt 1 189 nt 425
nt 225c nt 441
a Nucleotide immediately 59 of the recombination point; numbering
upstream (2) or downstream (1) from the first nucleotide of the HA
gene coding sequence.
b Nucleotide immediately 39 of the recombination point; numbering
from the first nucleotide of the helper RNA.
c The promoter site is in the polylinker downstream of the 26S
promoter and upstream of the HA gene coding sequence.
TABLE 3
Intracerebral Inoculation of Infant Mice with HA-VRP Packaged
with Single and Bipartite Helpers
Inoculuma Dose (IU)b PFUc Survivors/totald
Diluent 0 0 10/10
HA-VRP (BH) 53105 0 10/10
HA-VRP (BH) 53107 0 10/10
HA-VRP (SH) 53105 500 1/11
HA-VRP (SH) 53107 50000 0/10
a HA-VRP packaged with single (SH) and bipartite (BH) helper sys-
tems.
b Infectious units were determined as in Table 1.
c Plaque-forming units inoculated; PFU were determined by direct
plaque assay in Vero cells.
d Survivors/total number of animals inoculated. Samples of replicon
preparations (25 ml/animal) were inoculated ic into litters of 3-day-old
outbred ICR mice. Although VEE virus strain 3014 is avirulent in adult
mice inoculated sc at doses up to 2 3 105 (Davis et al., 1991), its LD50
following ic inoculation of infant mice was 1.5 PFU (data not shown;
Reed and Muench, 1938).
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Antibody responses in mice to HA, N, and VEE
induced by HA-VRP and N-VRP
The immunogenicity of VRP-vectored influenza HA or
Lassa N was determined by measuring antibody re-
sponses to the HA or N proteins following immunization
of BALB/c mice (Table 4). In the first set of experiments,
the HA-VRP and N-VRP used were prepared using the
monopartite V3014D520–7505 helper. Despite a low level
of contaminating infectious virus in these preparations
(Table 1), no clinical signs of infection were observed in
any of the inoculated animals regardless of the dose,
demonstrating the margin of safety afforded by the at-
tenuating mutations present in the V3014-derived helper.
Single sc inoculations of 3 3 105 or 3 3 107 IU of
HA-VRP induced dose-dependent, serum antibody re-
sponses to HA in all animals, and booster immunizations
resulted in significant increases in antibody titer (Table
4). In contrast, two inoculations of 3 3 103 IU of HA-VRP
induced little, if any, serum antibody in response to HA-
VRP. Thus, in this experiment, the minimum dose re-
quired to induce seroconversion in 100% of the mice with
a single inoculation was approximately 3 3 105 IU of
HA-VRP. Similarly, serum antibodies to Lassa N were
elicited by a single administration of 4 3 107 IU of N-VRP
or two inoculations of 4 3 105 IU. Serum antibodies to
VEE were present in a majority of the animals receiving
immunizing doses of HA- or N-VRP as a primary immu-
nization or following a booster (Table 4). The induction of
antibodies to VEE may have resulted from infection by
regenerated virus present in these preparations (Table 1)
or may have reflected an immune response to the struc-
tural components of the HA- or N-VRP themselves.
Sequential immunization with HA-VRP and N-VRP
prepared with the bipartite helper system
In contrast to VRP prepared with the monopartite
helper, regeneration of plaque-forming virus was not
detected in VRP prepared with the bipartite helper sys-
tem (Table 1). Groups of mice, which received two inoc-
ulations of 3 3 104 or 3 3 106 IU of N-VRP followed by
two inoculations of 2 3 105 IU of HA-VRP, all responded
with serum antibodies to both antigens (Fig. 4). A control
group of mice, which received two inoculations of HBSS
followed by two inoculations of 2 3 105 of HA-VRP,
responded with serum anti-HA antibody at a titer equiv-
alent to that in the sequentially inoculated animals. Con-
trol mice inoculated only with HBSS were negative for
antibodies to HA, N, or VEE. Therefore, with VRP pre-
pared with a bipartite helper, immunization with VRP
expressing Lassa N protein did not interfere with the
development of a response to subsequent primary im-
munization with VRP expressing the influenza HA.
ELISA antibody titer to VEE after four inoculations of
VRP prepared with the bipartite helper was below the
limit of detection (1:100) in 23 of 24 mice which received
VRP in this experiment, and the response in the remain-
ing animal was at a low level (1:200). Therefore, these
data suggest that the antibody responses to VEE de-
tected in the previous experiment, in which animals were
immunized with VRP produced with the monopartite
helper, were due to infection by attenuated, plaque-form-
TABLE 4
Induction of Serum Antibody by HA-VRP or N-VRP (Monopartite Helper) and Protection of BALB/c Mice against Influenzaa
Immunogen
Dose
(IU)b Anti-HA antibodyc Anti-N antibodyc Anti-VEE antibodyc
Morbidity after challenged
(sick total)
HBSS Primary (0) 0 ,102 (0/8) ,102 (0/8) ,102 (0/8)
Booster (32) 0 ,102 (0/8) ,102 (0/8) ,102 (0/8) 8/8
HA-VRP Primary (0) 3 3 107 1 3 103 (9/9) ,102 (0/9)
Booster (32) 3 3 107 4 3 104 (9/9) 1 3 103 (4/9) 0/8
HA-VRP Primary (0) 3 3 105 2 3 102 (9/9) ,102 (0/9)
Booster (32) 3 3 105 4 3 103 (9/9) 2 3 102 (8/9) 0/9
HA-VRP Primary (0) 3 3 103 ,102 (0/9) ,102 (0/9)
Booster (32) 3 3 103 ,102 (2/9) ,102 (0/9) 8/8
N-VRP Primary (0) 4 3 107 1 3 103 (5/5) 3 3 103 (5/5)
Booster (28) 4 3 107 5 3 104 (5/5) 8 3 103 (5/5) nde
N-VRP Primary (0) 4 3 105 ,102 (0/5) ,102 (0/5)
Booster (28) 4 3 105 2 3 103 (4/4) 2 3 102 (3/4) nd
a VRP were prepared in BHK cells with the V3014D520–7505 monopartite helper.
b Primary and booster immunizations were administered sc (HBSS; HA-VRP) or sc and ip (N-VRP) on the days indicated in parentheses.
c Geometric mean titers were determined by ELISA using purified influenza, Lassa, or VEE virion antigens. In parentheses, ratio of antibody-
positive/total animals is shown. Responses after primary and secondary inoculation were determined at days 28 and 70 postimmunization,
respectively.
d A challenge dose of 105 EID50 of influenza A/PR/8/34 was administered intranasally (day 116 postinoculation). The ratio of sick/total animals is
shown. Illness was determined by loss of at least 10% of body weight when measured at day 7 postchallenge.
e nd, not determined.
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ing virus rather than the result of repeated exposure to
the structural components of the VRP themselves.
Protection against a mucosal challenge with influenza
virus
Live, attenuated VEE vaccines elicit protection against
both parenteral and aerosol challenge with virulent VEE
(Jahrling and Stephenson, 1984). In a mouse model using
sc immunization with V3014 and i.n. challenge with wild-
type VEE, protection was demonstrated at nasal mucosal
surfaces (Charles et al., 1997). To determine if sc admin-
istration of VRP was capable of eliciting a protective
immune response to a mucosal pathogen, mice were
immunized with HA-VRP and subsequently challenged
by i.n. inoculation with influenza A/PR/8/34. Control
mice inoculated with HBSS or 3 3 103 IU of HA-VRP
showed no protection and significant weight loss after
influenza challenge (Table 4). In contrast, animals im-
munized with two doses of 3 3 105 or 3 3 107 IU of
HA-VRP showed no symptoms of disease after chal-
lenge, demonstrating that complete protection against
mucosal challenge could be elicited by parenteral
inoculation with HA-VRP.
Complete protection against influenza virus challenge
also was achieved in mice which received sequential
immunizations with N-VRP and HA-VRP prepared with
the bipartite helper (Fig. 4). In this experiment, surviving
control animals lost 20% of their body weight, and two of
four control mice died. No sickness, weight loss, or
death was seen in any of the mice which received im-
munizing doses of the HA-VRP, regardless of whether
they had received prior immunizations with VRP express-
ing the Lassa N protein.
DISCUSSION
Alphavirus expression systems hold great promise as
vaccine delivery vehicles, and the VEE-based replicon-
helper system described in this report is especially well
suited for this purpose. The VRP efficiently infect a vari-
ety of cultured cells in which they program high-level
synthesis of the vectored gene product, induce protec-
tive immunity in experimental animals, and do so in a
way which allows the sequential use of different VRP for
immunization of the same individuals against multiple
pathogens. Moreover, the combination of previously de-
fined attenuating mutations and the bipartite helper sys-
tem make VRP an inherently safe means of immuniza-
tion.
Expression in cultured cells
Like the SFV and Sindbis replicon systems, the VEE
vectors program high-level synthesis of heterologous
proteins in a wide range of cell types from different
species, including cells certified for production of human
vaccine products. An important determinant of high-level
expression of heterologous genes in Sindbis and SFV
replicon systems is the presence of a translational en-
hancer sequence embedded in the 59 end of the capsid
gene (Frolov and Schlesinger, 1994; Sjo¨berg and Garoff,
1996). The characteristic stem–loop structure of the SFV
and Sindbis translational enhancers is not present in the
VEE sequence. The VEE vectors described here retained
14 nucleotides of the authentic VEE 26S RNA followed by
a multiple cloning site into which the heterologous gene
was inserted. The Lassa N and influenza HA genes
utilized their native AUG initiator codons. Nevertheless,
the VEE replicon vectors expressed the Lassa N gene to
a level approximating 20% of the total cell protein. There-
fore, either efficient translation of the VEE subgenomic
26S mRNA does not require an enhancer element or an
FIG. 4. Sequential immunization of individual mice with N-VRP and
HA-VRP. Groups of BALB/c mice were inoculated sc on days 0 and 32
with either 3 3 104 IU (middle, small open arrows) or 3 3 106 IU
(bottom, large open arrows) of N-VRP (10 mice/group). Control animals
received HBSS at 0 and 32 days (top, open arrowheads; 5 mice/group).
On days 84 and 112, all animals received 2 3 105 IU of HA-VRP (solid
arrows). Animals were bled on the days indicated on the abscissa. Bars
show geometric mean serum antibody titers as measured by ELISA;
error bars represent one standard deviation. Open bars, titer to Lassa
N. Solid bars, titer to influenza HA.
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element with enhancer function is present in the primary
sequence of the 59 14 nucleotides of the VEE 26S mRNA.
Sequential immunization with VEE replicon particles
High levels of serum antibody to influenza HA and
Lassa N were induced by their respective VRP, and
complete protection against i.n. challenge with influenza
was obtained. One possible reason for the strength of
the response induced by VRP is that the glycoproteins of
VEE and VEE-based vectors target the virus to lymphoid
tissue (Gleiser et al., 1962; Gorelkin, 1973; Jackson et al.,
1991; Grieder et al., 1995; Davis et al., 1996; Caley et al.,
1997), an anatomical site highly favorable to induction of
immune responses. Moreover, immunization with HA-
VRP was demonstrated in animals which had been pre-
viously inoculated with N-VRP, and similar levels of hu-
moral antibody to influenza were induced whether or not
an individual animal had been immunized with N-VRP
previously. Preexisting or induced immunity to other virus
vectors, such as vaccinia, adenovirus, adeno-associated
virus, and herpesviruses, may limit their usefulness for
successive gene therapy or vaccine applications in a
given individual. Conversely, the most probable explana-
tion for the success of sequential VRP immunization was
the low level of antibody to the VEE structural proteins in
animals inoculated up to four times in succession with
VRP prepared with the bipartite helpers.
Several aspects of the VEE system may have contrib-
uted to the low level of anti-VEE antibody induction. First,
VRP stocks packaged with the bipartite helpers con-
tained very few if any plaque-forming virus particles, and
the VEE-specific antigenic mass represented by the VRP
themselves may have been insufficient for induction of
significant anti-VEE antibodies. Second, the titers of the
VRP preparations were high relative to the dose used for
immunization. Thus, any contaminating cell debris, which
would have contained significant levels of VEE structural
proteins, would have been removed by purification and
diluted by several orders of magnitude prior to inocula-
tion. Third, one would anticipate that the response to
both the expressed heterologous protein and the vector
itself would be affected significantly by the route of in-
oculation as well as the species immunized. While the
influence of these parameters, and of prior immunity to
VEE, is under active investigation, the present results
clearly demonstrate conditions where the VRP system
can be used for successful immunization against multi-
ple pathogens.
Copackaging and recombination of replicon and
helper RNAs
The presence of plaque-forming virus in alphavirus
replicon preparations is undesirable with respect to
immunization against the vector as well as safety. The
bipartite packaging system was designed to reduce
the probability that such virus would be generated
either by recombination or by copackaging of replicon
and helper RNAs in the same virion. In Sindbis sys-
tems, packaging of RNAs into particles appears to be
somewhat promiscuous. Sindbis replicon preparations
have particles which apparently contain helper RNAs
(Frolov et al., 1997) and plaque-forming particles in
which replicon and helper RNAs are copackaged (Gei-
genmu¨ller-Gnirke et al., 1991). In the former case,
co-infection of cells with helper-only RNA particles
along with replicon particles leads to the high-level
expression of the structural proteins. In the latter case,
structural protein expression will occur after infection
with copackaged particles, even at low m.o.i. In vivo,
either situation could result in the induction of immu-
nity to the vector. In contrast to Sindbis systems, no
evidence for copackaging of VEE replicon and helper
RNAs was observed.
Alphavirus recombination was first demonstrated ex-
perimentally with Sindbis virus (Weiss and Schlesinger,
1991), and sequence comparisons suggest that western
equine encephalitis virus is a naturally occurring recom-
binant between Sindbis and eastern equine encephalitis
virus (Hahn et al., 1988). Recombination between alpha-
virus replicon and helper RNAs during packaging also
can result in the generation of plaque-forming virus.
Although recombination occurs in infected cells at low
frequency, any recombinants generated during replicon
packaging will have a very large selective growth advan-
tage. This is of significant concern in the context of a
replicon particle vaccine, as contaminating recombinant
virus could compromise the safety of the replicon prep-
aration, and in vivo, growth of recombinants will induce
antibody to the virion structural proteins. In fact, Moss-
man et al., (1996) observed high titers of neutralizing
antibody to SFV in animals immunized with protease-
activated SFV replicon particles (Berglund et al., 1993), a
result which may have reflected infection by activated
recombinants or possibly infectious SFV regenerated by
second-site mutation (Salminen et al., 1992; Heidner et
al., 1994; Davis et al., 1995).
When VEE replicons were packaged by the V3014-
derived monopartite helper RNAs, the infectious virus
titers were, in general, inversely related to the size of the
deletion in the nonstructural protein genes. However,
exceptions to this generalization were evident, and sig-
nificant amounts of plaque-forming virus were obtained
even when the helper RNA contained less than 1 kb of
nonstructural gene sequence (V3014D520–7505). Of
three such plaque isolates sequenced, each derived
from an independent packaging experiment, all were
nonhomologous recombinants. Nonhomologous recom-
bination was observed previously between Sindbis
RNAs (Weiss and Schlesinger, 1991) and SFV RNAs
(Thomson and Dimmock, 1994). Each VEE recombinant
contained a 59 to 39 fusion between the replicon and
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helper RNAs at different sites within the HA insert (Table
2). Thus, the formation of viable recombinants did not
require the precise regeneration of the natural VEE se-
quence, as each recombinant contained two 26S promot-
ers with the second driving the transcription of the com-
plete structural gene region. Reducing the size of
homologous regions may have reduced the recombina-
tion rate, but sequence analysis of the recombinants
suggests the possibility that deletion of specific se-
quences in the helper RNA may have affected the rate of
nonhomologous recombination independently of dele-
tion size. Regardless of the mechanism, it is clear that
deletion of large portions of the nonstructural protein
genes from the monopartite helpers did not prevent the
regeneration of plaque-forming virus.
Replicon packaging with bipartite helper RNAs
It seems likely from our results and independent ex-
periments of others (Frolov et al., 1997) that although
recombination was occurring in the packaging cells, the
recombination requirements imposed by the use of bi-
partite helper RNAs greatly reduced the probability that a
plaque-forming, recombinant virus would be generated.
It is possible that a VRP preparation could contain
single recombinants in which the replicon RNA had re-
combined with only one of the structural protein helper
RNAs. Such single recombinants would not have regis-
tered as plaque-forming virus but would express a sub-
set of the VEE structural proteins upon infection of cells.
The incidence of single recombinants in the VRP prepa-
ration would be predicted at less than the frequency of
plaque-forming viruses found with the monopartite help-
ers, as these putative single recombinants would not
have been amplified by propagation subsequent to the
recombination event.
Role of attenuating mutations in the helper
glycoprotein genes
Although no plaque-forming virus was detectable in
these experiments, we anticipate that viable recombi-
nant viruses could be formed at some very low but still
finite frequency, and this likelihood necessitates addi-
tional precautions prior to use of alphavirus replicon
particles for immunization or gene therapy in humans.
To provide this extra margin of safety, we have utilized
helper glycoprotein genes which contain two strongly
attenuating mutations derived from V3014, a recombi-
nant VEE vaccine strain. V3014 is avirulent upon sc
inoculation of mice (Grieder et al., 1995) and horses
(Smith et al., unpublished observations), and therefore,
any recombinant generated during VRP packaging is
very likely to be at least as attenuated as V3014.
In summary, we have demonstrated that VRP pro-
gram high-level expression of a vectored gene in cul-
tured cells and in vivo can induce an efficacious im-
mune response against the pathogen from which that
gene was derived. The VRP are inherently safe in that
they are limited to a single cycle of infection, and this
level of safety is enhanced by the inclusion of atten-
uating mutations in the helper glycoproteins and the
use of a bipartite helper system which greatly reduces
the generation of infectious, plaque-forming virus. This
property also potentiates the use of these vectors for
sequential immunization of a given individual against
multiple pathogens. All of these characteristics make
the VEE replicon system with the bipartite helper a
flexible and attractive vaccine vector, especially in
situations where a live, attenuated vaccine might be
undesirable or difficult to develop.
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